News
PULM
4.070
+2.01%
0.080
Pulmatrix To Present Data On PUR1800 At The Annual Meeting Of The American Academy Of Allergy, Asthma And Immunology
Benzinga · 5d ago
Pulmatrix drops 18% after releasing early data for inhaled migraine therapy
Seeking Alpha · 01/04 15:35
Pulmatrix Says Formulated Inhaled Migraine Candidate Safe With Fewer GI Side Effects Compared To IV
Benzinga · 01/04 15:03
BRIEF-Pulmatrix Announces Positive Top Line Results From Phase 1 Study With PUR3100
Reuters · 01/04 14:06
Pulmatrix Reports Top-Line Results From Acute Migraine Treatment
Pulmatrix Reports Top-Line Results From Acute Migraine Treatment
MT Newswires · 01/04 10:52
Pulmatrix Q3 EPS $(1.45) Up From $(1.80) YoY, Sales $1.87M Up From $1.07M YoY
Benzinga · 11/10/2022 14:30
Pulmatrix GAAP EPS of -$1.45 beats by $0.06, revenue of $1.87M beats by $0.71M
Seekingalpha · 11/10/2022 14:12
-- Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.9M
-- Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.9M
MT Newswires · 11/10/2022 09:15
Pulmatrix Completes Patient Dosing for Phase 1 Study of Acute Migraine Drug Candidate
Pulmatrix Completes Patient Dosing for Phase 1 Study of Acute Migraine Drug Candidate
MT Newswires · 09/26/2022 11:44
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Spero Therapeutics (NASDAQ:SPRO) shares moved upwards by 122.7% to $1.83 during Thursday's pre-market session. The market value of their outstanding shares is at $64.1 million.
Benzinga · 09/22/2022 12:19
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Pulmatrix (NASDAQ:PULM) shares rose 11.9% to $4.3 during Wednesday's after-market session. The company's market cap stands at $14.5 million.
Benzinga · 09/21/2022 21:36
Why Splunk Is Trading Lower By Around 10%; Here Are 28 Stocks Moving Premarket
Gainers ECMOHO Limited (NASDAQ: MOHO) shares rose 47% to $0.2149 in pre-market trading.
Benzinga · 08/25/2022 12:12
Pulmatrix GAAP EPS of -$1.36 beats by $0.15, revenue of $1.33M beats by $0.17M
Pulmatrix press release (<span class="ticker-hover...
Seekingalpha · 08/08/2022 13:15
-- Earnings Flash (PULM) PULMATRIX Reports Q2 Revenue $1.33M
-- Earnings Flash (PULM) PULMATRIX Reports Q2 Revenue $1.33M
MT Newswires · 08/08/2022 09:15
Pulmatrix Commences Initial-Stage Acute Migraine Study
Pulmatrix (NASDAQ: PULM) has dosed first subject in its Phase 1 trial evaluating PUR3100 for the treatment of acute migraine. PUR3100 is an orally-inhaled Dihydroergotamine (DHE) acute migraine therapy.
Benzinga · 07/12/2022 15:03
Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100
Pulmatrix (NASDAQ:PULM) on Tuesday <a href="https://seekingalpha....
Seekingalpha · 07/12/2022 13:35
Pulmatrix Announces First Subject Dosed In Phase 1 Study Of PUR3100 For Acute Migraine
Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced the dosing
Benzinga · 07/12/2022 13:12
Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced the dosing of the first five subjects in a Phase 1 trial e...
PR Newswire · 07/12/2022 13:00
Pulmatrix Doses First Five Subjects in Phase 1 Trial of Potential Acute Migraine Treatment
MT Newswires · 07/12/2022 12:00
More
Webull provides a variety of real-time PULM stock news. You can receive the latest news about Pulmatrix through multiple platforms. This information may help you make smarter investment decisions.
About PULM
Pulmatrix, Inc. is a clinical-stage biotechnology company, which is focused on the discovery and development of inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs. It designs and develops inhaled therapeutic products based on its dry powder delivery technology, inhaled small particles easily respirable and emitted (iSPERSE), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. iSPERSE’s lead development program, Pulmazole is its inhaled formulation of itraconazole, an anti-fungal drug commercially available as an oral drug, which it is developing to treat and prevent pulmonary fungal infections. PUR1800 is developing for the treatment of acute exacerbations of chronic obstructive pulmonary disease and PUR3100 is developing for the treatment of acute migraine.